News
Articles
65th Czech and Slovak Psychopharmacological Conference
The main theme of this conference was sharing experience mainly in pharmacotherapy, but also in research and innovative approaches in treatment. And since one of our products is a pharmacogenetic test that investigates the genetic predisposition of drug metabolism, we were able to consult with physicians and offer this method to everyone as a way to make treatment more effective for patients.
Oncopanel expanded with new genes and the use of digitalMLPA
Genes tested by NGS: APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, EPCAM, ERCC2, ERCC3, FANCC, FANCM, FH, FLCN, GREM1, MET, MLH1, MLH3, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, POLD1, POLE, PRKAR1A, PTEN, PTCH1, RAD50, RAD51C, RAD51D, RET, SDHB, SLX4, SMAD4, SMARCB1, STK11, SUFU, TP53, VHL, WRN, WT1, UNC13D, MEN1, MITF, NTHL1, NF1, CHEK2, PMS2, RB1, PDK1, PDK2, PKHD1, PRSS1, PRSS2, SCG5, SPINK1, CTRC and HOXB13. Of which now newly introduced genes for NGS: MITF, PDK1, PDK2, PKHD1, PRSS1, PRSS2, SCG5, SPINK1, CTRC and HOXB13.
Enhanced testing of the DPYD gene
Following the recommendation of the European Medicines Agency CPIC (Clinical Pharmacogenetics Implementation Consortium), GHC Genetics laboratory has expanded testing of the DPYD gene (5-fluorouracil dosage) to test additional variants:
We have established cooperation with the Veronica patient organisation.
We are pleased to announce that in February we established cooperation with the Veronica patient organization. The Veronica patient organisation brings together patients with endometrial, vulvar, ovarian and cervical cancer and women with the BRCA 1 and BRCA 2 genetic mutations.